 |
인쇄하기
취소
|
HanAll initiate Phase I trial for oral formulation of human growth hormone
HanAll BioPharma Co. said Thursday it has initiate Phase I trial in Seoul National University Hospital for orally available protease resistant human growth hormone (HL-032).
This clinical study is designed to compare the safety of efficacy of HL-032 and Pfizer’s Genotropin injection in four groups, according to HanAll officials.
Preclinical studies have shown significantly higher bioavail...
This clinical study is designed to compare the safety of efficacy of HL-032 and Pfizer’s Genotropin injection in four groups, according to HanAll officials.
Preclinical studies have shown significantly higher bioavail...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.